The Small Molecule Inhibitor of SARS-CoV-2 3CLpro EDP-235 Prevents Viral Replication and Transmission in Vivo
Efficacy and Safety of EDP-235 in Nonhospitalized Adults With Mild or Moderate COVID-19: Results From the Phase 2 SPRINT Study
EDP-235, a Potent, Once-Daily, Oral Antiviral, Demonstrates Potential for Treatment and Prevention of Long COVID
EDP-235, an Oral 3CL Protease Inhibitor for the Treatment of COVID-19, Suppresses Viral Replication and Transmission in SARS-CoV-2-Infected Ferrets
High Throughput Screen to Identify Non-Nucleoside Small Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase
EDP-235, a Potent, Once-daily, Oral Antiviral, Demonstrates Excellent Penetration into SARS-CoV-2 Target Tissues, with the Potential for Mitigation of Viral Rebound in COVID-19 Patients
EDP-235, an Oral, Once Daily, Ritonavir-Free, 3CL Protease Inhibitor for the Treatment of COVID-19: Results from Phase 1 Study in Healthy Subjects
EDP-235, a Potent and Once-Daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes with the Potential for Mitigation of Cytokine Storm in COVID-19 Patients
EDP-235, a Potent and Once-Daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes with the Potential for Mitigation of Cytokine Storm in COVID-19 Patients